HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HBW Executive Decisions: Perrigo Science Chief, Clasada Supply Manager, FTC Appointment, More

Executive Summary

Democrat majority at FTC with Bedoya confirmation; Ives leads Perrigos science office; ACI appoints legal affairs director; Biomega promotes Norway factory manager; first leader for BBB National Programs’ outreach center; Embion adds commercial VP; and Clasado adds supply chain, corporate marketing heads.

You may also be interested in...



HBW Executive Decisions: Clasado Sales Heads, CRN Scholars, PanTheryx Early Nutrition SVP

Clasado appoints APAC, EMEA and North America sales directors; CRN, American Society for Nutrition award students; DSM Veteran joins PanTheryx as early life nutrition SVP; Ford chairs Abbott board as White leaves; and turnover at Turning Point helm.

Who You Gonna Call For US Oral Contraceptive Switch? Former FDA Official Heads Perrigo Americas

Jim Dillard, chief scientific officer for Perrigo since 2019, moves to head the North American business with research and development experience as well as a regulatory background from his work at the FDA.

Turning That Frown Upside Down: Treating Depression With Facial Botox Injections

In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152594

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel